Ownership and insider activity for Kymera Therapeutics, Inc. (KYMR): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Price
| Price | $127.51 (closing price, November 2, 2026) |
| Market Cap | $10.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | M-Exempt | 30,000 | $62K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 3,525 | $393K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 5,506 | $619K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 4,876 | $552K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 7,601 | $870K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 8,230 | $950K |
| 2026-10-01 | Mainolfi Nello | S-Sale | 262 | $30K |
| 2026-10-01 | Mainolfi Nello | M-Exempt | 30,000 | $62K |
| 2026-09-04 | Adams Brian | S-Sale | 1,209 | $140K |
| 2026-09-04 | Adams Brian | S-Sale | 3,025 | $353K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41.3M | $76.0M | $31.0M | $48.0M | $68.4M | $110.0M | $120.3M | $357.0M |
| Short-term Investments | 0 | $15.9M | $265.2M | $394.4M | $338.8M | $264.9M | $368.5M | $491.3M |
| Receivables | $148,000 | 0 | $1.4M | $135,000 | $2.5M | $18.8M | $947,000 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $41.8M | $92.8M | $302.3M | $451.3M | $419.4M | $405.3M | $510.3M | $871.2M |
| Property, Plant & Equipment | $2.2M | $22.1M | $20.7M | $21.3M | $22.2M | $101.1M | $97.9M | $85.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $44.2M | $116.7M | $487.2M | $605.9M | $603.1M | $575.8M | $978.0M | $1.74B |
| Accounts Payable | $2.1M | $3.3M | $4.4M | $4.0M | $4.3M | $7.1M | $6.0M | $4.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $13.8M |
| Total Current Liabilities | $4.7M | $34.6M | $110.6M | $92.5M | $71.3M | $85.7M | $67.8M | $83.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $78.7M | $191.1M | $203.3M | $146.3M | $113.0M | $180.8M | $142.4M | $163.1M |
| Retained Earnings | -$35.2M | -$76.5M | -$128.8M | -$229.0M | -$383.8M | -$530.8M | -$754.6M | -$1.07B |
| Total Equity | -$34.4M | -$74.4M | $283.9M | $459.6M | $490.2M | $395.0M | $835.6M | $1.58B |
| Total Debt | $695,000 | $21.2M | $18.0M | $18.0M | $17.3M | $84.7M | $87.8M | $82.3M |
| Net Debt | -$40.6M | -$70.8M | -$278.2M | -$424.5M | -$389.8M | -$290.2M | -$401.0M | -$766.0M |
| Working Capital | $37.1M | $58.3M | $191.7M | $358.7M | $348.1M | $319.6M | $442.5M | $788.0M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 11.13 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 23.20 |
Profitability
| Return on Equity | -22.39% |
| Return on Invested Capital | -23.94% |
| Return on Assets | -19.77% |
| Gross Margin | 174.52% |
| Operating Margin | -396.08% |
| Net Margin | -341.87% |
Related companies: NRIX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks